The economic burden of COPD

Chest. 2000 Feb;117(2 Suppl):5S-9S. doi: 10.1378/chest.117.2_suppl.5s.

Abstract

COPD is one of the leading causes of morbidity and mortality worldwide and imparts a substantial economic burden on individuals and society. Despite the intense interest in COPD among clinicians and researchers, there is a paucity of data on health-care utilization, costs, and social burden in this population. The total economic costs of COPD morbidity and mortality in the United States were estimated at $23.9 billion in 1993. Direct treatments for COPD-related illness accounted for $14.7 billion, and the remaining $9.2 billion were indirect morbidity and premature mortality estimated as lost future earnings. Similar data from another US study suggest that 10% of persons with COPD account for > 70% of all medical care costs. International studies of trends in COPD-related hospitalization indicate that although the average length of stay has decreased since 1972, admissions per 1,000 persons per year for COPD have increased in all age groups > 45 years of age. These trends reflect population aging, smoking patterns, institutional factors, and treatment practices.

MeSH terms

  • Adult
  • Aged
  • Cause of Death
  • Cost of Illness*
  • Cross-Sectional Studies
  • Female
  • Health Expenditures / statistics & numerical data
  • Humans
  • Incidence
  • Length of Stay / economics
  • Lung Diseases, Obstructive / economics*
  • Lung Diseases, Obstructive / etiology
  • Lung Diseases, Obstructive / mortality
  • Male
  • Middle Aged
  • United States / epidemiology